← Insider Monitor
Allogene Therapeutics, Inc. logo
ALLO

Allogene Therapeutics, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances)

1
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Allogene Therapeutics develops allogeneic (off-the-shelf) CAR T cell therapies derived from healthy donor cells, aiming to treat cancer patients without the need for patient-specific cell manufacturing used in traditional CAR T approaches.

Industry
Biological Products, (No Diagnostic Substances)
Headquarters
South San Francisco, CA
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Parker Geoffrey M.CHIEF FINANCIAL OFFICERSell$49KOct 21, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for ALLO.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable ALLO activity by email

Free alerts for the insider and congressional trades worth watching.

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.